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Abstract
Background: Abdominal aortic calcifications (AAC) predict cardiovascular mortality. A new scoring model for AAC,
the Morphological Atherosclerotic Calcification Distribution (MACD) index may contribute with additional
information to the commonly used Aortic Calcification Severity (AC24) score, when predicting death from
cardiovascular disease (CVD). In this study we investigated associations of MACD and AC24 with traditional
metabolic-syndrome associated risk factors at baseline and after 8.3 years follow-up, to identify biological
parameters that may account for the differential performance of these indices.
Methods: Three hundred and eight healthy women aged 48 to 76 years, were followed for 8.3 ± 0.3 years. AAC
was quantified using lumbar radiographs. Baseline data included age, weight, blood pressure, blood lipids, and
glucose levels. Pearson correlation coefficients were used to test for relationships.
Results: At baseline and across all patients, MACD correlated with blood glucose (r2 = 0.1, P< 0.001) and to a
lesser, but significant extent with traditional risk factors (p < 0.01) of CVD. In the longitudinal analysis of correlations
between baseline biological parameters and the follow-up calcification assessment using radiographs we found
LDL-cholesterol, HDL/LDL, and the ApoB/ApoA ratio significantly associated with the MACD (P< 0.01). In a subset
of patients presenting with calcification at both baseline and at follow-up, all cholesterol levels were significantly
associated with the MACD (P< 0.01) index. AC24 index was not correlated with blood parameters.
Conclusion: Patterns of calcification identified by the MACD, but not the AC24 index, appear to contain useful
biological information perhaps explaining part of the improved identification of risk of cardiovascular death of the
MACD index. Correlations of MACD but not the AC24 with glucose levels at baseline suggest that hyperglycemia
may contribute to unique patterns of calcification indicated by the MACD.
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Background
Cardiovascular disease (CVD) remains the leading cause
of mortality and major cause of morbidity worldwide,
with underlying atherosclerosis as one of the key ele-
ments. In more than 90% of cases, the cause of myocar-
dial ischemia is atherosclerotic plaque progression and
rupture which leads to thrombus formation and
obstruction of blood flow in the coronary arteries.
More than 50% of patients die without clinical symp-
toms [1]. To identify asymptomatic individuals at highest
risk, attempts have been made on developing tools to
risk-stratify individuals with sub-clinical atherosclerosis.
Many risk factors of atherosclerosis have been identi-
fied, of which the most widely accepted are elevated
total and low-density lipoprotein (LDL) cholesterol,
reduced high-density lipoprotein (HDL) cholesterol,
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hypertension, obesity, diabetes, and cigarette smoking
[2-4]. In the face of these well-recognized risk factors, it
is still debated whether postprandial serum triglyceride
levels are an independent predictor of cardiovascular
risk. Some studies have indicated that non-fasting trigly-
ceride levels are associated with incident of cardiovascu-
lar events independent of the traditional risk factors
whereas fasting triglyceride levels have displayed little
independent relationship [5,6]. In contrast, we have
demonstrated that fasting triglyceride levels in combina-
tion with specific distributions of adiposity are strong
predictors of accelerated atherosclerosis [7-9]. These
and other discrepancies highlight the need for additional
understanding of risk factors of CVD.
Non-invasive diagnostic tools, such as imaging techni-
ques, for identification of advanced atherosclerotic pla-
ques prior to manifestation of clinical symptoms, or
even death, would be clinically useful. Calcification of
coronary arteries has been shown to be directly related
to the severity and the extent of underlying coronary
plaque burden [10,11], and to be associated with
increased risk of coronary heart disease (CHD) [12-14].
A variety of imaging techniques for examining vascu-
lar calcifications have emerged with increasing attention
being focused on the assessment of abdominal aortic
calcifications from simple X-rays. Lumbar abdominal X-
ray for investigation of lumbar aortic calcification has
been shown to correlate with the extent of calcified pla-
ques in the coronary arteries [15-17]. These calcifica-
tions may be important risk factors of congestive heart
failure (CHF) independent of CHD and other risk
factors.
X-rays are traditionally analysed according to the cate-
gorical Framingham score system. We have recently
demonstrated [18,19] that additional information could
be harvested from these x-rays by including measures of
the number, length, width, and morphology of the calci-
fied plaques. Assessment of risk of CVD death using this
novel quantification system Morphological Atherosclero-
tic Calcification Distribution (MACD) quantification sys-
tem resulted in an odds ratio of 20 compared with 4.5
using the Framingham scoring systems [20]. Interestingly,
the MACD was associated with CVD death indepen-
dently of traditional risk factors including BMI, hyperten-
sion, obesity etc, suggesting that the MACD index
contained additional critically useful information.
The aim of the current study was to further investi-
gate the biological basis for the predictability of the
MACD index. In post-menopausal women as previously
described [18,19], we correlated traditional risk factors
with MACD scores in a cross-sectional and a longitudi-
nal study, and compared these correlations to the gold
standard, the AC24 index developed on the basis of the
Framingham Heart Study cohorts.
Methods
Subjects and Demographics
In 1992-93, 686 postmenopausal women living in the
Copenhagen area were recruited via questionnaire sur-
veys to participate in a study examining the role of a
number of metabolic risk factors in the pathogenesis of
CVD and osteoporosis. Follow-up was performed after
8.3 ± 0.3 years. Information from the 95 individuals who
died in the observation period was obtained via the Cen-
tral Registry of the Danish Ministry of Health with a fol-
low-up rate of 100%. A total of 129 women had
relocated from the Copenhagen area or did not wish to
participate in the follow-up period and provided no clin-
ical data at the end of the study. Baseline demographics
and risk parameters were not different between the
women who died or completed the study.
Among the 462 women completing the follow-up visit,
256 (55%) had radiographs in which the full lumbar (L1-
L4) aorta was visible on a single radiograph. Further-
more, among the deceased, 52 (55%) had X-ray exami-
nations in which the lumbar aorta was visible on a
single radiograph. Of these 52 deaths, 20 were related to
CVD (38%), 27 were related to cancer (52%) and 5 were
related to other causes (10%). The total number of
patients included in the final data set is 308.
All participants gave informed consent to participate
and the study was carried out according to the Helsinki
Declaration II and the European Standards of Good
Clinical Practice. Local ethical committees have
approved the study protocols.
At baseline and follow-up, data on age, weight, height,
Body Mass Index (BMI), waist and hip circumferences,
systolic and diastolic blood pressure (BP), and smoking
were collected. Fasting plasma glucose and the lipid pro-
file (total cholesterol, triglycerides, LDL-cholesterol
(LDL-C), HDL-cholesterol (HDL-C), apolipoprotein
ratio (ApoB/ApoB)) were obtained using an auto-analy-
zer (Cobas Mira Plus, Roche Diagnostics Systems, Hoff-
man-La Roche).
Assessment method of Abdominal Aortic Calcifications
Lateral X-rays of the lumbar aorta of all study partici-
pants (L1-L4) were recorded. The images were digitized
using a Vidar Dosimetry Pro Advantage scanner provid-
ing an image resolution of 9651 by 4008 pixels on 12-
bit gray scale using a pixel size of 44.6 μm2. Trained
radiologists were instructed to annotate the 6 points
used for vertebral height measurements [21] in the lum-
bar region L1- L4 on the digitized images, to delineate
the aorta, and to outline every individual calcified
deposit visible in the lumbar aorta while noting any
association to anterior and/or posterior aortic walls.
These readings recorded on a Sectra radiological reading
unit with annotation software implemented in Matlab
(Mathworks, MA, USA), allowed for the automatic
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computation of both the 0-24 aortic calcifications
(AC24) severity score and the MACD [18]. The software
used allowed editing and digital zoom.
The inter- and intra-observer variability of the radiolo-
gist’s outlines of the AAC’s was computed on a subset
of 8 images with four annotations each. The mean Jac-
card Index between the radiologists’ AAC outlines was
0.56 for the intra-observer variation and 0.51 for the
inter-observer variation. The two radiologists had an
intra-observer variability of 0.53 and 0.59, respectively.
A newly developed aortic calcification index, MACD
[18] was quantified from outlines of the calcified aortic
plaques on the X-rays from the lumbar aorta at baseline
and compared with scores derived from the same
patients using the aortic calcification severity score,
AC24. MACD is given by
MACD = NCD · MAD,
where NCD is the Number of Calcified Deposits and
given by the number of distinct calcified deposits in the
lumbar region (L1-L4), as visualised in Figure 1. MAD is
the Morphological Atherosclerotic Distribution factor
and can be explained in the following way: X-ray analy-
sis only visualises the calcified core and not the biologi-
cal extend of the atherosclerotic lesions. As a
consequence, we estimate the atherosclerotic plaque size
from the area and form of the observed calcified lesion.
This is done by quantization of not only the calcified
part, but also pixels within a predefined distance of the
calcification. Elongated and circular plaques of similar
size do not count equally: the estimated plaque around
the elongated calcification will be larger than the esti-
mated plaque around the circular calcification of similar
size, as visualised in Figure 1. Thus, equal areas of
calcification with different morphologies will have differ-
ent scores. The MAD factor is hence described mathe-
matically by
MAD =
sim
area
,
where sim is the simulated area described below and
area is the area of the calcified plaque visible on the
radiograph. The simulated area is implemented by iter-
ated morphological dilations [18] with a combined
radius of 200 pixels (corresponding to 8.9 mm) simulat-
ing the total extent of the atherosclerotic process. The
radius of 200 pixels of the increment was found after
experiments with about 30 images, which are a subset
of our population. In summary, the MAD factor
describes the growth potential of the calcified plaques.
Statistical Evaluation
Data is expressed as means ± SEM unless otherwise indi-
cated. For analysis of the relation between metabolic
markers and calcification markers the calcified popula-
tion is divided into quartiles according to the calcification
marker. As AC24 is categorical, patients are divided into
quartiles Q1-Q4 according to their AC24 scores and into
bins of similar size using the continuous MACD. Preli-
minary inspection showed that the highest quartile (Q4)
stands out in biomarker values compared to Q1-Q3.
Hence, we tested difference between Q4 and Q1 and also
Q4 to Q1-Q3, where we pooled quartiles to get larger
groups and drive significance. Differences to Q1 were
never significant. All concentrations were log-trans-
formed and visually inspected for normality. Differences
were tested with two-sided t-tests. Similarly, patients
were divided according to standard clinical thresholds for
the metabolic markers and the difference in calcification
markers in the two groups was tested with a non-para-
metric Mann-Whitney U test since calcification markers
cannot be assumed to be normally distributed. Tests
were considered significant when p < 0.05.
Results
Baseline characteristics of the biochemical parameters
for the 308 women who participated in this study are
shown in Table 1. The mean age of the total population
at baseline was approximately 60 years, with individuals
with AACs at baseline having a significantly higher aver-
age age. There was a significant difference in systolic
blood pressure, total cholesterol, LDL cholesterol,
ApoB/ApoA, triglycerides, glucose, and BMI between
the subgroup of patients (n = 165) with no calcifications
at baseline, and the subgroup of patients (n = 143) pre-
senting with aortic calcifications at baseline. Figure 2
illustrates the population subgroups at baseline and fol-
low-up visits. Furthermore, Table 2 illustrates the
Figure 1 Examples of scores for the AC24 and MACD index
according to the size and distribution of the aortic
calcifications. Only MACD is influenced by both size and
distribution of the lesions.
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calcification status of the study population at baseline
and at follow up.
Cross-sectional analysis
The MACD index was compared to the AC24 score
with the respect to their respective relation to biological
parameters. Differences between the highest quartile of
calcified patients and the remainder of calcified patient
(group C) are shown in Table 3.
The baseline MACD index was significantly positively
associated to baseline blood glucose levels and triglycer-
ides, ApoB/ApoA, and LDL/HDL ratio whereas the
AC24 score was not (Table 3). A detailed overview of
glucose levels and triglycerides separated after MACD in
quartiles is given in figure 3. In the cross-sectional fol-
low-up analysis (Table 4) significance disappeared
except for plasma glucose levels, which now was also
positively associated to AC24. No significant associa-
tions were observed for the cholesterol levels.
Table 5 shows the baseline association of calcification
markers after stratification of patients according to stan-
dard clinical thresholds. Among the ones investigated,
lipids, triglyceride level and LDL level associated posi-
tively to both MACD and AC24. Systolic blood pressure
showed positive association to both calcification markers.
Longitudinal analysis - Progression of disease and
initiation of disease was analyzed
Table 6 and 7 show the association of follow-up (FU)
MACD and AC24 to the different biological parameters.
Among all patients progressing in the disease irrespec-
tively of disease status (SC group (n = 135)) the FU-
MACD associated significantly with blood lipids (trigly-
ceride, total cholesterol, and LDL), whereas AC24 did
not associate to any of the lipid parameters. Both FU-
MACD and FU-AC24 were significantly positively asso-
ciated to systolic blood pressure. Among patients with
disease progression (group S (n = 103)) the same pat-
tern of associations was discovered.
Assessment of indexes which might be associated with
the initiation of aortic calcification (group S+, the group
with no calcification at baseline (n = 32)) indicated that
neither the MACD index nor AC24 did show any signif-
icant association to any of the biological parameters at
follow-up.
Discussion
The newly established MACD index was recently shown
to be four-fold superior to conventional risk assessment
scoring systems, in predicting the CVD related deaths
[18]. We examined associations of calcification image
biomarkers with other risk factors in order to investigate
whether specific biological blood profiles were particu-
larly associated with the MACD index compared to the
conventional AC24 score.
Table 1 Characteristics of the study population stratified into whole population, healthy (H) at baseline, with no
calcifications identified, and population with calcifications (C) at baseline
Population (n = 308) H (n = 165) C (n = 143)
Age (years) 60.3 ± 7.5 57.8 ± 6.8 63.3 ± 7.1 **
BMI (kg/m2) 24.7 ± 3.9 25.1 ± 3.8 24.3 ± 4.0
Systolic BP (mm Hg) 127 ± 21 122 ± 19 133 ± 23 **
Diastolic BP (mm Hg) 77 ± 10 76 ± 10 77 ± 10
Hypertension 48 16 32
Glucose (mmol/L) 4.74 ± 1.10 4.59 ± 0.56 4.92 ± 1.44 *
Total-C. (mmol/L) 6.33 ± 1.19 6.11 ± 1.00 6.58 ± 1.27 **
Triglyceride (mmol/L) 1.24 ± 0.75 1.20 ± 0.69 1.41 ± 0.81 *
LDL-C/mmol/L) 2.89 ± 0.82 2.71 ± 0.69 3.09 ± 0.91 **
HDL-C/mmol/L) 1.37 ± 0.36 1.38 ± 0.34 1.35 ± 0.39
ApoB/ApoA 0.57 ± 0.18 0.53 ± 0.15 0.61 ± 0.20 **
LDL/HDL 2.32 ± 1.08 2.14 ± 0.92 2.53 ± 1.21
* p < 0.05; ** p < 0.01; *** p < 0.001; (*) p < 0.1 borderline significant
Figure 2 Study population and the sub-populations.
Barascuk et al. BMC Cardiovascular Disorders 2011, 11:75
http://www.biomedcentral.com/1471-2261/11/75
Page 4 of 9
The main findings in the cross-sectional study (Table
3) were the highly significant correlation of the MACD
index to glucose and triglyceride levels as well as ApoB/
ApoA and LDL/HDL ratio compared to that of the
AC24 score that did not display any correlation to the
two parameters. Furthermore, cross-sectional analysis of
the follow-up data displayed a significant correlation to
the plasma glucose levels for both the MACD index and
the AC24 score emphasizing the importance of glucose
for disease progression. The data from the cross-sec-
tional part of the study suggests that an index based on
plaque distribution and morphology, such as the MACD
index, contains additional information, in terms of its
dynamic sensitivity to traditional risk factors.
The longitudinal analysis was performed in order to
assess if there were differences in the biological profiles
of patients with and without CVD at baseline in relation
to the MACD index and AC24 score. There was a large
difference in the significance of biochemical factors in
the groups with and without calcification at baseline
(Table1). When analyzing the group of patients with the
increased number of calcifications (SC group n = 135)
in their lumbar aorta from baseline to follow-up (Table
6 and 7), we found that the MACD index was highly
associated with biochemical parameters such as trigly-
cerides, total cholesterol and LDL cholesterol compared
to the AC24 score. The MACD index and the AC24
score both correlated with systolic blood pressure. The
longitudinal study indicated that the MACD is a more
sensitive index in comparison to the AC24 score, when
evaluating the CVD risk in patients having arterial
calcifications.
Surprisingly, this picture changes when examining the
group of patients with detectable calcifications at follow-
up, but not at baseline (S+ group n = 32). This group of
patients was used under the current analysis to investi-
gate the early stages in initiation of calcifications.
Neither the MACD nor the AC24 score displayed any
significant correlation to the biochemical parameters
investigated. An obvious caveat is the smaller number of
patients (n = 32) in this sub-group compared to the
patients progressing in the disease (n = 103).
MACD index vs. AC24 score
The observed differences in the MACD index and AC24
score in correlation to biochemical factors in the exam-
ined sub-groups may be explained by the differences in
the scoring technique. As visualized in Figure 1, there
are important differences between the AC24 and
MACD indexes. The MACD score gives importance to
each of the calcified deposits present, whereas only
those deposits that are positioned in non-scored areas
are included in the AC24 index. For example, the AC24
score doesn’t counts two calcified deposits positioned
right next to each, but looks only at their projection to
the wall (see Figure 1, middle). Thereby the MACD is
Table 2 Overview of the groups in our study population according to patient calcification status at baseline and
follow-up
Calcification Status No calcification at Follow-up Calcifications at Follow-up Death at Follow-up
Calcifications at Baseline - S (n = 103) DC (n = 40)
No Calcifications at Baseline SH (n = 121) S+ (n = 32) DH (n = 12)
Table 3 Cross-sectional analysis - division of different biological risk factors into quartiles based on AC24; Here
presented mean plus/minus standard error of the mean and results of a two-sample t-test between the highest
quartile and the combination of the lowest three quartiles with baseline biochemistry and baseline X-rays
Baseline-Baseline MACD Group C
Lowest three quartiles
n = 116
MACD Group C
Highest quartile
n = 27
MACD Group C
p-value
AC24 Group C
Lowest three quartiles
n = 116
AC24 Group C
Highest quartile
n = 27
AC24 Group C
p-value
Age 63.08 ± 0.66 64.24 ± 1.39 - 62.84 ± 0.67 65.28 ± 1.25 -
Triglyceride 1.28 ± 0.07 1.95 ± 0.20 p = .0002 1.35 ± 0.07 1.65 ± 0.19 -
BMI 24.28 ± 0.37 24.37 ± 0.79 - 24.36 ± 0.38 24.04 ± 0.70 -
Systolic BP 133.06 ± 2.10 134.07 ± 4.48 - 132.41 ± 2.17 136.85 ± 3.72 -
Diastolic BP 77.97 ± 0.95 73.89 ± 1.67 - 77.24 ± 0.94 77.04 ± 1.97 -
Total-C 6.58 ± 0.11 6.62 ± 0.30 - 6.62 ± 0.12 6.45 ± 0.22 -
Glucose 4.76 ± 0.09 5.60 ± 0.5 p = .0120 4.83 ± 0.13 5.30 ± 0.30 -
LDL-C 3.06 ± 0.08 3.20 ± 0.23 - 3.08 ± 0.09 3.14 ± 0.15 -
HDL-C 1.38 ± 0.04 1.22 ± 0.08 - 1.38 ± 0.04 1.24 ± 0.08
Apo B/Apo A 0.59 ± 0.02 0.71 ± 0.05 p = .0035 0.60 ± 0.02 0.67 ± 0.04 -
LDL/HDL 2.43 ± 0.11 2.98 ± 0.28 p = .0389 2.46 ± 0.11 2.87 ± 0.25 -
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influenced to a greater degree by an increased number
of calcified plaques. In addition, the MACD index favors
smaller plaques compared to larger plaques for their
potential to grow. This is done by dividing the simulated
plaque area estimating the total atherosclerotic area
from the visualized calcified core by the actual calcified
core area. These subtle although important differences
in the two indexes may have significant biological impli-
cations, for factors initiating and/or driving the disease.
A possible caveat of this specialized feature may be the
more tailored performance for long follow-up periods.
The MACD index may have different distribution of
plaque number and morphologies that result in the
same score. For example, many smaller plaques would
have a higher score compared to an equal area of large
plaques. Thereby the same amounts of calcification
assessed by the MACD score may change significantly
over time, both resulting in lower and higher risk.
Thereby the MACD index may be a more dynamic
assessment of score and risk. In support of this, recent
investigation suggests that calcium content of the plaque
may be proportional to the risk of rupture until a cer-
tain point, at which the evolving plaque becomes a
more stable plaque [18]. This biological feature is
accounted for in the modulation of the potential to
grow of smaller plaques.
Plasma Glucose and CVD-risk
One of our main findings at baseline demonstrated a
strong correlation of high plasma glucose levels with
MACD but not with the AC24 index. At follow up,
cross-sectional analysis, we found significant association
of both MACD index and AC24 score with glucose
levels (Table 3 and 4, and figure 3a). This suggests a
Figure 3 Glucose level (a) and triglyceride level (b) for the
baseline-calcified population in quartiles according to MACD.
Table 4 Cross-sectional analysis - division of different biological risk factors into quartiles based on AC24; Here
presented mean plus/minus standard error of the mean and results of a two-sample t-test between the highest
quartile and the combination of the lowest three quartiles
Follow-Up-
Follow-Up
FU-MACD Group SC
Lowest three
quartiles
n = 106
FU-MACD Group
SC
Highest quartile
n = 29
FU-MACD Group
SC
p-value
FU-AC24 Group SC
Lowest three
quartiles
n = 106
FU-AC24 Group
SC
Highest quartile
n = 29
FU-AC24 Group
SC
p-value
Age 68.98 ± 0.67 73.54 ± 1.28 p = .0019 69.43 ± 0.69 72.18 ± 1.32 -
Triglyceride 1.43 ± 0.07 1.45 ± 0.11 - 1.45 ± 0.07 1.39 ± 0.12 -
BMI 25.47 ± 0.45 24.60 ± 0.77 - 25.33 ± 0.43 25.21 ± 0.97 -
Systolic BP 155.59 ± 2.71 160.41 ± 4.76 - 153.88 ± 2.47 168.50 ± 5.87 p = .0111
Diastolic BP 83.51 ± 1.09 81.97 ± 2.29 - 82.62 ± 1.07 85.79 ± 2.38 -
Total-C 6.11 ± 0.11 6.24 ± 0.22 - 6.14 ± 0.12 6.13 ± 0.18 -
Glucose 5.50 ± 0.10 6.17 ± 0.31 p = .0100 5.51 ± 0.10 6.17 ± 0.32 p = .0148
LDL-C 2.88 ± 0.08 3.02 ± 0.17 - 2.91 ± 0.09 2.92 ± 0.15 -
HDL-C 1.63 ± 0.04 1.66 ± 0.09 - 1.63 ± 0.04 1.66 ± 0.09
Apo B/Apo
A
0.60 ± 0.02 0.61 ± 0.04 - 0.60 ± 0.02 0.62 ± 0.04 -
LDL/HDL 1.86 ± 0.07 1.97 ± 0.16 - 1.88 ± 0.07 1.92 ± 0.16 -
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strong predisposing role of glucose in atherogenesis.
Diabetes is now generally considered being one of the
major risk factors of atherosclerosis, with the hypergly-
cemia as an underlying contributing factor [22]. Patients
with diabetes have been found to present with distinct
calcifications of the medial part of the arteries often
referred to as Monckenberg’s medial sclerosis, which is
associated with vascular stiffening and atherosclerosis
[23-26]. Intimal calcifications may occur independently
of medial calcifications and vice versa [27]. In diabetic
patients, medial calcification seems to be a strong inde-
pendent predictor of cardiovascular mortality and occurs
particularly in patients with nephropathy [28,29]. How-
ever, mechanisms that mediate vascular complications
following hyperglycemia are not yet fully understood.
Blood-lipids and CVD-risk
Our second major cross-sectional finding demonstrates
that plasma triglyceride levels correlated with the
MACD index in the baseline cross-sectional study
(Table 3 and 4 and figure 3b), adding to the body of evi-
dence that triglycerides are of considerable importance
in atherogenesis.
Elevated serum triglycerides in the high-risk patients
and the role of hypertriglyceridemia as causality of cor-
onary artery disease remain to be elucidated. Nonethe-
less, there is growing evidence that hypertriglyceridemia
is a marker for increased risk for coronary artery disease
[30-33]. Our data further support this notion, both in
the cross-sectional and the longitudinal part of the
study. Importantly, the triglycerides correlate signifi-
cantly the MACD-index, but not AC24, emphasizing the
importance and differences of this new scoring method.
It should also be emphasized that the observed strong
baseline correlation of blood lipids, disappeared in the
follow-up cross-sectional study. We have previously
shown [18] that the high-risk group of patients in our
cohort presented with OR of approximately 20,
Table 5 Division of MACD and AC24 into halves based on clinical thresholds
Baseline-Baseline MACD All
Smaller
MACD All
Larger
MACD All
p-value
AC24 All
Smaller
AC24 All
Larger
AC24 All
p-value
Triglyceride (< 1.69/> = 1.69) 236/60 patients 60.93 ± 7.21 151.82 ± 28.61 p = .0130 1.51 ± 0.16 2.28 ± 0.38 -
BMI (< 25/> = 25) 183/125 patients 80.22 ± 9.75 78.38 ± 14.21 - 1.87 ± 0.19 1.38 ± 0.22 -
Systolic BP (< 119/> = 119) 104/204 patients 48.92 ± 11.17 95.05 ± 10.78 p = .0003 0.94 ± 0.19 2.04 ± 0.19 -
Diastolic BP (< 70/> = 70) 58/250 patients 64.84 ± 19.04 82.87 ± 9.04 - 1.17 ± 0.29 1.78 ± 0.16 -
Total Cholesterol (< 5/> = 5) 30/266 patients 87.77 ± 34.74 78.40 ± 8.53 - 1.63 ± 0.51 1.67 ± 0.15 -
Glucose (< 5/> = 5) 219/77 patients 68.76 ± 8.42 109.48 ± 21.48 - 1.54 ± 0.17 2.04 ± 0.33 -
LDL Cholesterol (< 2.6/> = 2.6) 114/184
patients
56.95 ± 11.41 93.50 ± 11.47 p = .0071 1.05 ± 0.19 2.04 ± 0.21 p = .0019
HDL Cholesterol (< 1.55/> = 1.55) 212/86
patients
89.06 ± 10.92 56.00 ± 10.48 - 1.83 ± 0.18 1.26 ± 0.23 -
Mean plus/minus standard error of the mean and results of a Mann-Whitney U-test between the halves made of baseline MACD and AC24
Table 6 Longitudinal analysis - division of different biological risk factors into quartiles based on AC24
Follow Up-
Baseline
FU-MACD Group SC
Lowest three
quartiles
n = 106
FU-MACD Group
SC
Highest quartile
n = 29
FU-MACD Group
SC
p-value
FU-AC24 Group SC
Lowest three
quartiles
n = 106
FU-AC24 Group
SC
Highest quartile
n = 29
FU-AC24 Group
SC
p-value
Age 60.21 ± 0.67 65.23 ± 1.3 p = .0007 60.69 ± 0.69 63.77 ± 1.33 p = .0433
Triglyceride 1.24 ± 0.05 1.51 ± 0.13 p = .0439 1.30 ± 0.06 1.28 ± 0.11 -
BMI 24.48 ± 0.40 24.01 ± 0.58 - 24.44 ± 0.36 24.23 ± 0.90 -
Systolic BP 125.28 ± 1.78 139.48 ± 4.60 p = .0008 126.08 ± 1.94 137.86 ± 3.84 p = .0065
Diastolic BP 76.23 ± 1.00 77.59 ± 2.03 - 76.42 ± 1.02 77.14 ± 2.02 -
Total-C 6.39 ± 0.11 7.14 ± 0.25 p = .0048 6.52 ± 0.12 6.63 ± 0.21 -
Glucose 4.74 ± 0.09 4.90 ± 0.30 - 4.72 ± 0.09 4.99 ± 0.30 -
LDL-C 2.96 ± 0.08 3.42 ± 0.19 p = .0197 3.02 ± 0.08 3.23 ± 0.16 -
HDL-C 1.33 ± 0.03 1.34 ± 0.08 - 1.34 ± 0.03 1.29 ± 0.08 -
Apo B/Apo A 0.59 ± 0.02 0.66 ± 0.05 - 0.59 ± 0.02 0.63 ± 0.04 -
LDL/HDL 2.44 ± 0.11 2.84 ± 0.26 - 2.46 ± 0.12 2.77 ± 0.22 -
Mean plus/minus standard error of the mean and results of a two-sample t-test between the highest quartile and the combination of the lowest three quartiles
with baseline biochemistry and baseline X-rays for the SC group follow-up biological risk factors
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according to the MACD index. The explanation for the
slightly improved blood-lipid picture at follow-up could
partly be due to the death of some of the patients in
this group during the 7.5 years between baseline and
follow-up visit. Furthermore, as the age in the popula-
tion increases, the treatments in form of blood-lipid
lowering medication increases in our population, which
could contribute to the understanding of the sudden
lack of significant correlations of both the MACD index
and the AC24 score to blood lipids. We do not have
information on the number of patients receiving lipid-
lowering medication in our study population.
Limitations of the Study
The sample size is a limitation of the present study. The
relatively small population with only 20 CVD deaths, a
limited representation of ethnicity and gender and a
mixture of death causes may limit the generalizability of
our results. Furthermore, the lack of information about
lipid lowering treatments is a problem of a historical
study.
Conclusion
In conclusion, we have demonstrated that a refined
index of arterial aortic calcification, MACD, may contain
additional and important information on risk related to
cardiovascular mortality compared to the traditional
AC24 index. This index correlated significantly to emer-
ging risk factors in atherosclerosis. Further studies in
larger cohorts are needed to further differentiate and
understand the relative importance of MACD index
compared to that of the AC24 score. In the present stu-
dies, each index provided important information. How-
ever, whereas the MACD index correlated to both
initiation and progression of disease, the AC24 corre-
lated only in relation to initiation of disease.
Study limitations
The present study has its limitations. Its findings are
only valid for a follow-up period of 8.5 years and may
not necessarily apply to shorter follow-up periods. For
short follow-up times, the predictive power could possi-
bly be based only on the total plaque burden as
described by the AC24 score. Furthermore, the present
population is restricted in size, geographical and ethnic
content to postmenopausal Danish women. The present
study needs validation in other populations and longer
term clinical settings, preferably supported by the histo-
logical evaluations.
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Table 7 Longitudinal analysis - division of different biological risk factors into quartiles based on AC24
Follow Up-
Baseline
FU-MACD Group S
Lowest three
quartiles
n = 76
FU-MACD
Group S
Highest quartile
n = 27
FU-MACD
Group S
p-value
FU-AC24 Group S
Lowest three
quartiles
n = 76
FU-AC24
Group S
Highest quartile
n = 27
FU-AC24
Group S
p-value
Age 61.37 ± 0.76 65.24 ± 1.40 p = .0126 61.79 ± 0.80 64.06 ± 1.34 -
Triglyceride 1.22 ± 0.06 1.51 ± 0.14 p = .0421 1.29 ± 0.07 1.29 ± 0.12 -
BMI 24.21 ± 0.49 23.76 ± 0.60 - 24.10 ± 0.43 24.07 ± 0.92 -
Systolic BP 128.55 ± 2.11 139.07 ± 4.83 p = .0231 128.95 ± 2.34 137.96 ± 3.98 -
Diastolic BP 77.17 ± 1.12 77.22 ± 2.16 - 77.24 ± 1.14 77.04 ± 2.09 -
Total-C 6.36 ± 0.13 7.10 ± 0.27 p = .0124 6.53 ± 0.15 6.60 ± 0.21 -
Glucose 4.82 ± 0.12 4.89 ± 0.32 - 4.78 ± 0.12 4.99 ± 0.31 -
LDL-C 2.98 ± 0.09 3.38 ± 0.21 p = .0633 3.03 ± 0.10 3.23 ± 0.17 -
HDL-C 1.34 ± 0.04 1.33 ± 0.08 - 1.37 ± 0.04 1.27 ± 0.08 -
Apo B/Apo A 0.59 ± 0.02 0.66 ± 0.05 - 0.59 ± 0.02 0.64 ± 0.04 -
LDL/HDL 2.43 ± 0.13 2.84 ± 0.28 - 2.43 ± 0.14 2.81 ± 0.23 -
Mean plus/minus standard error of the mean and results of a two-sample t-test between the highest quartile and the combination of the lowest three quartiles
with baseline biochemistry and baseline X-rays for the S group follow-up biological risk factors.
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